Unusual 11 Mid-Day Movers 07/17: (ANTH) (DGIT) (PPHM) Higher; (EDU) (ALU) (MFRM) Lower
Tweet Send to a Friend
Down)
Anthera Pharma (Nasdaq: ANTH) 30.1% HIGHER; continuing higher following an 87 percent surge yesterday on the heels of additional positive data related to its Phase 2b PEARL-SC trial.
New Oriental Education (NYSE: EDU) 28.8% LOWER; is leading Chinese stocks lower Tuesday following disclosure of an SEC investigation earlier. Click here to see the full report.
DG (Nasdaq: DGIT) 25.8% HIGHER; to explore strategic alternatives, including partnerships, strategic business model alternatives, a sale or other transaction. DG has engaged Goldman, Sachs and Co. in conjunction with the exploration of strategic alternatives.
Peregrine Pharmaceuticals (Nasdaq: PPHM) 18.9% HIGHER; reported Q4 EPS of ($0.10), $0.03 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $2.07 million versus the consensus estimate of $2.64 million.
Alcatel-Lucent (NYSE: ALU) 18.3% LOWER; sees Q2 adjusted operating loss of around €40 million with revenues above €3.5 billion. Looking ahead, based on the current order book, Alcatel-Lucent expects the second half of 2012 to be better than the first half, but in light of year-to-date performance and the difficult macro-economic environment, Alcatel-Lucent will not be able to achieve its previously announced adjusted operating margin guidance for the full-year 2012.
Allos Therapeutics (Nasdaq: ALTH) 18.2% HIGHER; the stock plunged 19 percent over the last 20 minutes of trade yesterday as shares broke below the 50- and 200-day simple moving averages. Traders are buying the dip this morning.
Complete Genomics (Nasdaq: GNOM) 16.5% HIGHER; higher today following the acquisition of Navigenics, Inc., by Life Technologies (Nasdaq: LIFE), as reported late Monday. Financial terms of the deal weren't disclosed.
Mattress Firm (Nasdaq: MFRM) 16.0% LOWER; boosted its Q2 adj-EPS guidance from 35-50 cents to 38-40 cents and its GAAP estimate from 26-29 cents to 27-29 cents. Quarterly sales guidance was lowered from $270-$275 million to $260-$265 million. The FY12 non-GAAP outlook moved from $1.63-$1.69 to $1.65-$1.71 and the GAAP outlook was raised from $1.46-$1.50 to $1.48-$1.52. The FY12 sales outlook was reduced from $1.03-$1.06 billion to $1.01-$1.03 billion.
Fuel Tech, Inc. (Nasdaq: FTEK) 15.3% HIGHER; was awarded the largest air pollution control contract in its history. The $36.6 million order, placed by E.CL S.A., a major utility in Chile, includes turnkey installation of Low NOx Burners (LNBs) and Over-Fire Air (OFA) systems and mill modernization for six coal-fired units. Equipment deliveries are scheduled to commence during the first quarter of 2013, with project completion occurring during the third quarter of 2014.
AuRico Gold (NYSE: AUQ) 15.1% LOWER; the company's CEO Rene Marion stepped down. The company also announced production results for Q2 yesterday. Click here to see the full report.
StanCorp (NYSE: SFG) 11.1% LOWER; expecting Q2 adj-EPS of 51 cents, which compares to the Street estimate of 86 cents. Sees its previously-issued FY12 EPS outlook of $3.60-$3.90 to be below guidance. The Street estimate is $3.57.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
New Oriental Education (NYSE: EDU) 28.8% LOWER; is leading Chinese stocks lower Tuesday following disclosure of an SEC investigation earlier. Click here to see the full report.
DG (Nasdaq: DGIT) 25.8% HIGHER; to explore strategic alternatives, including partnerships, strategic business model alternatives, a sale or other transaction. DG has engaged Goldman, Sachs and Co. in conjunction with the exploration of strategic alternatives.
Peregrine Pharmaceuticals (Nasdaq: PPHM) 18.9% HIGHER; reported Q4 EPS of ($0.10), $0.03 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $2.07 million versus the consensus estimate of $2.64 million.
Alcatel-Lucent (NYSE: ALU) 18.3% LOWER; sees Q2 adjusted operating loss of around €40 million with revenues above €3.5 billion. Looking ahead, based on the current order book, Alcatel-Lucent expects the second half of 2012 to be better than the first half, but in light of year-to-date performance and the difficult macro-economic environment, Alcatel-Lucent will not be able to achieve its previously announced adjusted operating margin guidance for the full-year 2012.
Allos Therapeutics (Nasdaq: ALTH) 18.2% HIGHER; the stock plunged 19 percent over the last 20 minutes of trade yesterday as shares broke below the 50- and 200-day simple moving averages. Traders are buying the dip this morning.
Complete Genomics (Nasdaq: GNOM) 16.5% HIGHER; higher today following the acquisition of Navigenics, Inc., by Life Technologies (Nasdaq: LIFE), as reported late Monday. Financial terms of the deal weren't disclosed.
Mattress Firm (Nasdaq: MFRM) 16.0% LOWER; boosted its Q2 adj-EPS guidance from 35-50 cents to 38-40 cents and its GAAP estimate from 26-29 cents to 27-29 cents. Quarterly sales guidance was lowered from $270-$275 million to $260-$265 million. The FY12 non-GAAP outlook moved from $1.63-$1.69 to $1.65-$1.71 and the GAAP outlook was raised from $1.46-$1.50 to $1.48-$1.52. The FY12 sales outlook was reduced from $1.03-$1.06 billion to $1.01-$1.03 billion.
Fuel Tech, Inc. (Nasdaq: FTEK) 15.3% HIGHER; was awarded the largest air pollution control contract in its history. The $36.6 million order, placed by E.CL S.A., a major utility in Chile, includes turnkey installation of Low NOx Burners (LNBs) and Over-Fire Air (OFA) systems and mill modernization for six coal-fired units. Equipment deliveries are scheduled to commence during the first quarter of 2013, with project completion occurring during the third quarter of 2014.
AuRico Gold (NYSE: AUQ) 15.1% LOWER; the company's CEO Rene Marion stepped down. The company also announced production results for Q2 yesterday. Click here to see the full report.
StanCorp (NYSE: SFG) 11.1% LOWER; expecting Q2 adj-EPS of 51 cents, which compares to the Street estimate of 86 cents. Sees its previously-issued FY12 EPS outlook of $3.60-$3.90 to be below guidance. The Street estimate is $3.57.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- 50-Day SMA Crossers 05/20: (ELN) (ACI) (AAPL) Above; (MRK) (TLAB) (CLSN) Below
- Notable Mergers and Acquisitions of the Day 05/16: (DDR) (BRC) (MLNX)
- Notable 52-Week Highs and Lows of the Day 05/15: (RAD) (SCTY) (TSO) High; (SHZ) (AU) Low
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Unusual 11 Mid-Day Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
